Norwegian University Of Science And Technolology

6 trials 1 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

4 Completed trials

8 Countries active

8 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 2 Phase II: 4

Oversight events:

1 unexpected event across 1 trial

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

ATEZOLIZUMAB 1 BOTULINUM TOXIN TYPE A 1 DURVALUMAB 1 GLUTAMATE DECARBOXYLASE 2, HUMAN, RECOMBINANT 1 HUMAN PLASMA PROTEIN 1 LUTETIUM (177LU) ZADAVOTIDE GURAXETAN 1 SODIUM CHLORIDE 1

All trials

6 total

68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma Pending

2024-518495-31-00 Phase II 1 country LUTETIUM (177LU) ZADAVOTIDE GURAXETAN
The BASIC study Recruiting

2024-515166-14-00 Phase III 2 countries BOTULINUM TOXIN TYPE A; SODIUM CHLORIDE
Testing LADA diabetes status 3 years after treatment with intranodal GAD-alum. Ended

2023-509021-53-00 Phase II 2 countries GLUTAMATE DECARBOXYLASE 2, HUMAN, RECOMBINANT
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten… Ended

2023-505514-15-00 Phase III 5 countries DURVALUMAB
The ExPlas Study Ended

2024-518668-11-01 Phase II 1 country HUMAN PLASMA PROTEIN
A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-… Ended

2024-515755-37-00 Phase II 5 countries ATEZOLIZUMAB

Showing 1–6 of 6 trials

← All sponsors A–Z